🇺🇸 FDA
Company

Kyverna

Kyverna Therapeutics

KYTX biotech USA

Quick answer

Kyverna is a biotech company (KYTX) headquartered in EMERYVILLE, CA, USA with 10 tracked pipeline programs.

Pipeline (10)

project

Standard of Care Treatment

Myasthenia Gravis

Phase 3 · small_molecule · active

1 trials project

KYV-101

Multiple Sclerosis, Primary Progressive

Phase 2 · mab · active

1 trials project

KYV-101

Systemic Sclerosis

Phase 2 · mab · active

1 trials project

KYV-101 anti-CD19 CAR-T cell therapy

Lupus Nephritis

Phase 2 · mab · active

2 trials project

KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy

ANCA-IgG-positive ANCA Associated Vasculitis

Phase 2 · small_molecule · active

1 trials project

KYV101

Rheumatoid Arthritis

Phase 2 · small_molecule · active

1 trials project

Standard lymphodepletion regimen

Stiff-Person Syndrome

Phase 2 · mab · active

1 trials project

KYV-101

Idiopathic Inflammatory Myopathies

Phase 1 · small_molecule · active

1 trials project

KYV-101 (Biological) - 0.33 ×10^8 cells

Progressive Multiple Sclerosis

Phase 1 · mab · active

1 trials project

KYV-101 anti-CD19 CAR-T cell therapy

Multiple Sclerosis

Phase 1 · mab · active

1 trials

Patents (2)

patent

US 11879003

Methods for increasing T-cell function

Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11446357

Method for treating disease using FOXP3+CD4+ T cells

Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)